Literature DB >> 400732

Degradation and secretion of insulin in hepatic cirrhosis.

Y Iwasaki, A Ohkubo, H Kajinuma, Y Akanuma, K Kosaka.   

Abstract

To clarify the mechanism of hyperinsulinism of hepatic cirrhosis, plasma insulin and C-peptide levels before and after oral glucose loads were measured in 34 patients with cirrhosis, 15 patients with chronic hepatitis, and 25 normal subjects. While plasma immunoreactive insulin (IRI) levels during oral glucose tolerance testing (OGTT) were significantly increased in cirrhotics, plasma immunoreactive C-peptide (CPR) levels were elevated slightly. The C-peptide to insulin ratio throughout OGTT was significantly smaller in cirrhotics than in normal subjects (P less than 0.01). A decreased hepatic insulin degradation rate has been suggested to one of the main causes of hyperinsulinism in hepatic cirrhosis. The ratio of the difference between basal and 30-min CPR values and basal and 30-min OGTT blood glucose values [delta CPR: delta BS(30)'] as well as the delta IRI: delta BS(30') ratio was significantly decreased in cirrhotics (P less than 0.01). These results indicate that insulin secretion in response to a glycemic stimulus is reduced in cirrhotics. Both the ratios of the sums of six IRS and CPR values of OGTT (sigma CPR: sigma IRI) and delta CPR: delta BS(30') and sigma CPR: sigma BS(30') were found in inverse relationship with indocyanine green retention rate in cirrhotics.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 400732     DOI: 10.1210/jcem-47-4-774

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

3.  Insulin and C-peptide in ascitic fluid and plasma and their relative responses to glucagon in patients with cirrhosis.

Authors:  S Akgün; A Samanta; N H Ertel
Journal:  J Endocrinol Invest       Date:  1988-12       Impact factor: 4.256

4.  Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.

Authors:  L Gerö; L Korányi; F Szalay; B Büki; G Tamás
Journal:  Acta Diabetol Lat       Date:  1982 Jan-Mar

5.  Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis.

Authors:  G Marchesini; G P Bianchi; G Forlani; A G Rusticali; D Patrono; M Capelli; M Zoli; P Vannini; E Pisi
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

6.  Insulin and C-peptide plasma levels in patients with severe chronic pancreatitis and fasting normoglycemia.

Authors:  E Bonora; C Rizzi; C Lesi; P Berra; C Coscelli; U Butturini
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

7.  Fractional hepatic extraction of insulin in man: is it constant?

Authors:  E Bonora; L Capretti; V Manicardi; I Zavaroni; C Coscelli; U Butturini
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

8.  Effects of intra- and extrahepatic portal systemic shunts on insulin metabolism.

Authors:  K Ohnishi; A Mishima; M Takashi; S Tsuchiya; S Iida; S Iwama; N Goto; K Kono; Y Nakajima; N Suzuki; H Musha; K Okuda
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

9.  Plasma levels of insulin, C-peptide and glucagon in liver cirrhosis.

Authors:  G Gragnoli; A M Signorini; I Tanganelli
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

10.  Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect.

Authors:  P Cavallo-Perin; M Cassader; C Bozzo; A Bruno; P Nuccio; A M Dall'Omo; M Marucci; G Pagano
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.